Skip to search formSkip to main contentSkip to account menu

Icotinib Hydrochloride

An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BPI-2009H
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Therapeutic Effect of CT-Guided 125I Seed Implantation Combined with Icotinib Hydrochloride on Unresectable Non-Small Cell Lung Cancer
To evaluate the clinical application of icotinibhydrochloride chemotherapy combined with CT-guided 125I seedimplantation in the… 
2014
2014
Progression of pharmacology and clinical study of icotinib hydrochloride
Non-small cell lung cancer( NSCLC) accounts for about 80%-85% of lung cancer. The main treatment of advanced NSCLC is medical… 
2013
2013
Clinical Observation of Icotinib Hydrochloride in the Treatment for Advanced Non-small Cell Lung Cancer
[Purpose] To evaluate the efficacy and toxicities of icotinib in 42 patients with advanced NSCLC.[Methods] Forty-two patients… 
2010
2010
A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China.
7574 Background: To assess the safety, tolerance and efficacy of icotinib hydrochloride (BPI-2009H), a new selective EGFR TKI in… 
2009
2009
Icotinib hydrochloride polymorphs, pharmaceutical compositions, and uses
The present invention relates to 4 - [(3-ethynylphenyl) amino] - quinazoline and [6,7-b] -12- crown-4 hydrochloride Form II, III…